Taken together, our data suggests that combination therapy with dual-targeting IL-6 and CD40 with checkpoint blockade robustly reverses Mφ-mediated immune suppression, leading to T-cell infiltration and activation in GBM. This evidence concerns the gene IL6 and glioblastoma.